Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Cona, Ferrara, Italy.
Rheumatology Division, Multispecialist Medical Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Clin Exp Rheumatol. 2022 Jul;40(7):1247-1257. doi: 10.55563/clinexprheumatol/1sjgyr. Epub 2022 Jul 4.
New evidence for the treatment of rheumatoid arthritis (RA) has emerged during the last year. Specifically, updated guidelines on pharmacological and non-pharmacological management of RA have emphasised the necessity of global patient's care, and have shifted the role of some older drugs, such as glucocorticoids and methotrexate. In addition, the long-term safety of Janus kinase inhibitors was investigated and reinforced. With respect to the coronavirus-19 pandemic, reassuring data on the efficacy and safety of vaccinations in the RA population were acquired, as well as on the potential role of telemedicine in RA management. Machine learning prediction models and biomarkers development have emerged as promising innovations in the area of precision/personalised medicine, appearing to encourage future expansion.In this narrative review, the authors aim to give their specific point of view on the most relevant and potentially impacting novelties published during 2021 and early 2022 in the context of RA management.
过去一年中出现了类风湿关节炎（RA）治疗的新证据。具体来说，关于 RA 的药物和非药物治疗的更新指南强调了全面患者护理的必要性，并改变了一些较老药物（如糖皮质激素和甲氨蝶呤）的作用。此外，还对 Janus 激酶抑制剂的长期安全性进行了研究和加强。关于冠状病毒-19 大流行，RA 人群中疫苗的疗效和安全性获得了令人安心的数据，以及远程医疗在 RA 管理中的潜在作用。机器学习预测模型和生物标志物的开发已成为精准/个体化医学领域的有前途的创新，似乎鼓励未来进一步发展。在这篇叙述性综述中，作者旨在就 2021 年和 2022 年初发表的与 RA 管理相关的最相关和最具潜在影响的新内容发表他们的具体观点。
